GlaxoSmithKline has notified healthcare professionals of recent safety data regarding the use of rosiglitazone to treat female patients with type 2 diabetes mellitus. The results of a clinical trial showed that more female patients who received rosiglitazone experienced fractures of the upper arm, hand, or foot, than did female patients who received either metformin or glyburide. Healthcare providers should consider the risk of fracture when initiating or treating female diabetic patients with rosiglitazone.

For more information visit